Table 1 Antibody-drug conjugates in clinical trials for lymphoma
From: Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
ADC | Target | Linker | Payload | Indication | Result | Trial |
|---|---|---|---|---|---|---|
ADCs approved for lymphoma | ||||||
Brentuximab vedotin | CD30 | Val-Cit | MMAE | R/R HL | ORR 75%, CR 34% | phase II [48] |
R/R HL | ORR 54.4%, median PFS 8.2Â months | phase III [49] | ||||
R/R HL | ORR 75%, CR 42% | phase I [51] | ||||
Post-ASCT consolidation for HL | Median PFS 42.9Â months, 5-year PFS 59% | phase III [52] | ||||
Post-ASCT consolidation for HL | 18-month PFS 95%, 18-month OS 98% | phase II [53] | ||||
Salvage therapy for R/R HL | 2-year OS 95%, 2-year PFS 74% | phase II [54] | ||||
Salvage therapy for R/R HL | ORR 84%, CR 79% | phase II [55] | ||||
Salvage therapy for R/R HL | ORR 85%, CR 67%, 2-year PFS 78% | phase I/II [56] | ||||
Untreated HL | ORR 86%, CR 73%, 5-year PFS 82% | phase III [58] | ||||
Untreated HL | ORR 61%, CR 48% | phase II [59] | ||||
R/R ALCL and R/R MF | ORR4 56.3%, CR 16%, median PFS 17.2Â months | phase III [60] | ||||
R/R CTCL and R/R PTCL | ORR 38%, CR 17% | phase II [61] | ||||
Untreated PTCL | ORR 83%, CR 68%, 5-year PFS 51% | phase III [63] | ||||
Untreated ALCL | 2-year EFS 79%, 2-year OS 97% | phase II [64] | ||||
R/R PMBCL and R/R mediastinal GZL | PMBCL: ORR 73%, CR 37% Mediastinal GZL: ORR 70%, CR 50% | phase I/II [67] | ||||
Untreated PMBCL, DLBCL, and GZL | ORR 100%, CR 86%, 2-year PFS 85%, | phase I/II [68] | ||||
Polatuzumb vedotin | CD79b | Val-Cit | MMAE | R/R DLBCL and R/R FL | FL: ORR 70%, CR 45%; DLBCL: ORR 54%, CR 21% | phase II [71] |
R/R DLBCL | ORR 45%, CR 40%, median OS 12.4Â months, | phase II [25] | ||||
R/R DLBCL | ORR 65%, CR 31%, median DOR 5.8Â months | phase I/II [72] | ||||
R/R FL | ORR 76%, CR 65% | phase I/II [73] | ||||
Untreated DLBCL | ORR 89%, CR 77% | phase I/II [74] | ||||
Loncastuximab tesirine | CD19 | Val-Ala | PBD dimer | R/R NHL | ORR 46%, CR 27%, median DOR 5.4Â months | phase I [76] |
R/R DLBCL | ORR 48%, CR 24%, median DOR 10.3Â months | phase II [78] | ||||
ADCs explored in clinical settings | ||||||
Coltuximab ravtansine | CD19 | SPDB | DM4 | R/R DLBCL | ORR 44%, CR 15% | phase II [79] |
R/R DLBCL | ORR 31% | phase II [81] | ||||
SGN-CD19A | CD19 | MC | MMAF | R/R B-NHL | ORR 33%, CR22%, median DOR 40Â weeks | phase I [82] |
MT-3724 | CD20 | / | SLTA | R/R DLBCL | ORR 30%, CR 10% | phase I [100] |
Inotuzumab ozogamicin | CD22 | Acid-labile | Calicheamicin | R/R NHL | FL: ORR 87%, 2-year PFS 68% DLBCL: ORR 74%, 2-year PFS 42% | phase III [88] |
R/R NHL | ORR 41%, 18-month OS 35% | phase III [89] | ||||
R/R NHL | ORR 53%, CR 20% | phase I [90] | ||||
R/R B-NHL | ORR 84%, CR 24% | phase I [91] | ||||
R/R indolent B-NHL | ORR 67%, CR 31%, median PFS 12.7Â months | phase II [92] | ||||
Pinatuzumab vedotin | CD22 | Protease-cleavable | MMAE | R/R DLBCL and R/R indolent NHL | DLBCL: ORR 36%, Indolent NHL: ORR 50% | phase I [96] |
R/R DLBCL and R/R FL | DLBCL: ORR 60%, CR 26%; FL: ORR 62%, CR 5% | phase II [71] | ||||
TRPH-222 | CD22 | Non-cleavable | Maytansinoid | R/R NHL | ORR 27.2%, CR 22.7% | phase I [97] |
R/R HL | ORR 69%, CR 44%, median DOR 7.7Â months, median PFS 6.7Â months | phase I [109] | ||||
IMGN529 | CD37 | SMCC | DM1 | R/R B-NHL | ORR 13% | phase I [113] |
AGS67E | CD37 | Val-Cit | MMAE | R/R NHL | ORR 22%, CR 14% | phase I [116] |
STRO-001 | CD74 | Non-cleavable | Maytansinoid | Advanced B cell malignancies | ORR 25%, CR 6.3% | phase I [125] |
Iladatuzumab vedotin | CD79b | Protease-cleavable | MMAE | R/R B-NHL | ORR 85%; DLBCL: ORR 60%, CR 43% | phase I [128] |
VLS-101 | ROR1 | UC-961 | MMAE | R/R NHL | MCL: ORR 47%, CR 20%; DLBCL: ORR 80%, CR 40% | phase I [131] |